Pfizer broke ground on a $50 million expansion at its Chesterfield campus that reflects the company’s increased investment in biopharmaceuticals. The expansion doubles the size of a pilot plant that produces protein-based, injectable biologic drugs for clinical trials. “We’re relative novices at this, but we’ve got some really exciting things early on in the pipeline,” said John LaMattina, Pfizer’s outgoing head of global R&D. Pfizer currently has fou...